Bio-isobutene Contracts for Technip/IPSB

French renewables company IBN-One, a joint venture between Cristal Union and Global Bioenergies, has awarded a contract for initial engineering work on its proposed bio-isobutene plant to a consortium of Technip and IPSB, a specialist engineer in sugar and biotechnologies. The plant will be the first in France that converts renewable resources into isobutene. Global Bioenergies has granted IBN-One a non-exclusive technology license for the plant which will have a capacity of 50,000 t/y.

The first front-end engineering design phase will run for 12 months and precedes the detailed engineering studies, contracts for which will be awarded at a later date. Bernard Chaud, chairman and CEO of IBN-One and director of industrial strategy at Global Bioenergies, said that during this first phase, engineers will specify the equipment design and the connections between the plant’s different sub-units, as well as its integration at a Cristal Union sugar beet site.

IPSB will be responsible for engineering the plant’s upstream segment, which is dedicated to the intake of raw material from the neighboring sugar mill and converting it to bio-isobutene by fermentation. Construction is expected to start in early 2018.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.